Literature DB >> 21592864

NKT-cell-based immunotherapies in clinical trials.

Mark A Exley, Toshinori Nakayama.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21592864     DOI： 10.1016/j.clim.2011.04.015

Source DB:  PubMed          Journal:  Clin Immunol        ISSN： 1521-6616            Impact factor:   3.969


× No keyword cloud information.
  16 in total

1.  Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

Authors:  Aristeidis Chaidos; Scott Patterson; Richard Szydlo; Mohammed Suhail Chaudhry; Francesco Dazzi; Edward Kanfer; Donald McDonald; David Marin; Dragana Milojkovic; Jiri Pavlu; John Davis; Amin Rahemtulla; Katy Rezvani; John Goldman; Irene Roberts; Jane Apperley; Anastasios Karadimitris
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113

Review 2.  Prevention and treatment of type 1 diabetes mellitus by the manipulation of invariant natural killer T cells.

Authors:  Jan Novak; Lucie Novakova
Journal:  Clin Exp Med       Date:  2012-07-24       Impact factor: 3.984

3.  Human invariant NKT cell subsets differentially promote differentiation, antibody production, and T cell stimulation by B cells in vitro.

Authors:  Shijuan Grace Zeng; Yasmeen G Ghnewa; Vincent P O'Reilly; Victoria G Lyons; Ann Atzberger; Andrew E Hogan; Mark A Exley; Derek G Doherty
Journal:  J Immunol       Date:  2013-07-12       Impact factor: 5.422

4.  Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses.

Authors:  Reem Ghinnagow; Julie De Meester; Luis Javier Cruz; Caroline Aspord; Stéphanie Corgnac; Elodie Macho-Fernandez; Daphnée Soulard; Josette Fontaine; Laurence Chaperot; Julie Charles; Fabrice Soncin; Fathia Mami-Chouaib; Joel Plumas; Christelle Faveeuw; François Trottein
Journal:  Oncoimmunology       Date:  2017-08-18       Impact factor: 8.110

5.  Human CD1d knock-in mouse model demonstrates potent antitumor potential of human CD1d-restricted invariant natural killer T cells.

Authors:  Xiangshu Wen; Ping Rao; Leandro J Carreño; Seil Kim; Agnieszka Lawrenczyk; Steven A Porcelli; Peter Cresswell; Weiming Yuan
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

6.  Dendritic cells tolerized with adenosine A₂AR agonist attenuate acute kidney injury.

Authors:  Li Li; Liping Huang; Hong Ye; Steven P Song; Amandeep Bajwa; Sang Ju Lee; Emily K Moser; Katarzyna Jaworska; Gilbert R Kinsey; Yuan J Day; Joel Linden; Peter I Lobo; Diane L Rosin; Mark D Okusa
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

7.  Natural killer T cells: drivers or passengers in preventing human disease?

Authors:  Stuart P Berzins; David S Ritchie
Journal:  Nat Rev Immunol       Date:  2014-08-08       Impact factor: 53.106

8.  The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy.

Authors:  Telma Lança; Bruno Silva-Santos
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

9.  CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.

Authors:  Gengwen Tian; Amy N Courtney; Bipulendu Jena; Andras Heczey; Daofeng Liu; Ekaterina Marinova; Linjie Guo; Xin Xu; Hiroki Torikai; Qianxing Mo; Gianpietro Dotti; Laurence J Cooper; Leonid S Metelitsa
Journal:  J Clin Invest       Date:  2016-05-16       Impact factor: 14.808

10.  A Subset of CD8αβ+ Invariant NKT Cells in a Humanized Mouse Model.

Authors:  Xiangshu Wen; Seil Kim; Ran Xiong; Michelle Li; Agnieszka Lawrenczyk; Xue Huang; Si-Yi Chen; Ping Rao; Gurdyal S Besra; Paolo Dellabona; Giulia Casorati; Steven A Porcelli; Omid Akbari; Mark A Exley; Weiming Yuan
Journal:  J Immunol       Date:  2015-07-08       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.